Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children

Vaccine

Volumn 18, Issue 15, 2000, Pages 1467-1472

  Duval, B ^a   Boulianne, N ^a   De Serres, G ^a   Laflamme, N ^a   De Wals, P ^b   Masse R ^c   Trudeau, G ^d   Delage, G ^e   Desjardins, L ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c Dir Gen de la S Publique   (Canada)

^d Dir S Pub du Saguenay Lac St Jean   (Canada)

^e INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Hepatitis B, vaccination; Immunigenicity

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

BLOOD SAMPLING; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

CHILD; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; MALE; VACCINES, SYNTHETIC;

EID: 0033970557     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00422-3     Document Type: Conference Paper

References (35)

1. Zajac B.A., West D.J., McAleer W.J., Scolnick E.M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J. Infect. 13:1986;39-45.
2. Bock H.L., Kruppenbacher J., Sänger R., Höbel W., Clemens R., Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch. Int. Med. 156:(19):1996;2226-2231.
3. West D.J. Clinical experience with hepatitis B vaccines. Am. J. Infect. Control. 17:(3):1989;172-180.
4. André F.E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 8:1990;74-78.
5. Milne A., Brawner T.A., Dumbill P.C., Kawachi I., Pearce N.E. Comparison of the immunogenicity of reduced doses of two recombinant DNA hepatitis B vaccines in New Zealand children. J. Med. Virol. 27:1989;264-267.
6. Schiff G.M., Sherwood J.R., Zeldis J.B., Krause D.S. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J. Adolesc. Health. 16:1995;12-17.
7. Poovorawan Y., Pongpunlert W., Theamboonlers A., Vimolgej L., Chumdermpadetsuk S., Vandepapeliere P., Safary A. Randomized, single-blind comparison of the immunogenicity and reactogenicity of 20 μg and 10 μg doses of hepatitis B vaccine in adolescents. Southeast Asian J. Trop. Med. Public Health. 24:(21):1993;255-259.
8. West D.J., Calandra G.B., Ellis R.W. Vaccination of infants and children against hepatitis B. Ped. Clin. North Am. 37:(3):1990;585-601.
9. Tsega E, Tafesse B, Horton J, Nordenfel E, Wolde-Hawariat G, Hansson BG, Lindberg J. Immunogenicity, reactogenicity and comparison of two doses of recombinant DNA yeast-derived hepatitis B vaccine in Ethiopian children. Trop Geograph Med 1991. p. 220-227.
10. André F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am. J. Med. 87:(Suppl. 3a):1989;14-20.
11. Kane M. Reduced doses of hepatitis B vaccines: is it a good idea? Bull. WHO. 73:(4):1995;529-530.
12. Treadwell T.L., Keeffe E.B., Lake J., Read A., Friedman L.S., Goldman I.S., Howell C.D., De Medina M., Schiff E.R., Jensen D.M., Koff R.S. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am. J. Med. 95:1993;584-588.
13. Dahl-Hansen E., Siebke J.C., Froland S.S., Degre M. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers. Epidemiol. Infect. 104:1990;143-149.
14. Hammond G.W., Parker J., Mimms L., Tate R., Sekla L. Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines. Vaccine. 9:1991;97-100.
15. Crovari P., Cuneo-Crovari P., Icardi G.C., Bonanni P., Coppola R.C. Immunization of young adults with two yeast derived hepatitis B vaccines, abstracted. J. Med. Virol. 21:1987;99A.
16. André F.E. Two superb vaccines against hepatitis B in Mexican standoff. JAMA. 259:(16):1988;2402-2403.
17. Rustgi V.K., Schleupner C.J., Krause D.S. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults. Vaccine. 13:(17):1995;1665-1668.
18. Greenberg D.P., Vadheim C.M., Wong V.K., Marcy M., Partridge S., Greene T., Chiu C.Y., Margolis H.S., Ward J.I. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Ped. Infect. Dis. J. 15:(7):1996;590-596.
19. Booy R. Getting Hib vaccine to those who need it. Lancet. 351:1998;1446-1447.
20. Hollinger B. Hepatitis B vaccines: to switch or not to switch. JAMA. 257:(19):1987;2634-2636.
21. Hollinger F.B. Two superb vaccines against hepatitis B in Mexican standoff. JAMA. 259:(16):1998;2404.
22. Duval B., Boulianne N., De Serres G., De Wals P., Massé R., Trudeau G., Delage G., Desjardins L., Safary A. Should children with isolated anti-HBs or anti-HBc be immunized against hepatitis B virus? JAMA. 278:(13):1997;1064.
23. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., Osterholm M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA. 270:(24):1993;2935-2938.
24. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B vaccines. Am. J. Prev. Med. 15:(1):1998;1-8.
25. West D.J., Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 14:(11):1996;1019-1027.
26. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR. 40:(RR-13):1991;1-25.
27. Guide Canadien d'immunisation. 5th ed. Ass. Med. Can. 1998;124-137.
28. Lagos R., Valenzuela M.T., Levine O.S., Losonsky G.A., Erazo A., Wasserman S.S., Levine M.M. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet. 351:1998;1472-1476.
29. FDA approval of change in pediatric formulation for recombivax HB. MMWR. 48:(2):1999;34-35.
30. Goh K.T., Tan K.L., Kong K.H., Oon C.J., Chan S.H. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. Bull. WHO. 70:(2):1992;233-239.
31. Gellin B.G., Greenberg R.N., Hart R.H., Bertino J.S.J., Stein D.H., Deloria M.A., Clements-Mann M.L. Immunogenicity of two doses of yeast recombinant hepatitis B vaccine in healthy older adults. J. Infect. Dis. 175:1997;1494-1497.
32. Marsano L.S., West D.J., Chan I., Hesley T.M., Cox J., Hackworth V., Greenberg R.N. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine. 16:(6):1998;624-629.
33. Ambrosch F, Wiedermann G, Garcon N, Leroux-Roels G, Slaoui M, Thoelen S. A hepatitis B vaccine formulated with a novel adjuvant system. In: ICAAC, San Diego, CA, 1998.
34. Van Herck K, Van Damme P, Thoelen S. 1998. A combined hepatitis A and hepatitis B vaccine administered in a two-dose schedule to adolescents. In: 38th ICAAC, San Diego, CA. p. H.
35. Bryan J.P., MacArthy P., Rudock A., Fogarty J.P., Dowd H., Legters L.J., Perine P.L. Hepatitis B vaccine booster dose: low-dose recombinant hepatitis B vaccines as a booster dose. Am. J. Infect. Control. 25:(3):1997;215-222.